Alpha Family Trust Buys 9,430 Shares of Bristol-Myers Squibb (NYSE:BMY)

Alpha Family Trust grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 101.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 18,760 shares of the biopharmaceutical company's stock after buying an additional 9,430 shares during the period. Alpha Family Trust's holdings in Bristol-Myers Squibb were worth $971,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. First Foundation Advisors boosted its position in shares of Bristol-Myers Squibb by 20.1% in the 1st quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 548 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Bristol-Myers Squibb by 76.1% in the 1st quarter. Acadian Asset Management LLC now owns 620,324 shares of the biopharmaceutical company's stock valued at $33,632,000 after acquiring an additional 268,006 shares during the last quarter. Catalytic Wealth RIA LLC increased its stake in shares of Bristol-Myers Squibb by 33.1% in the 1st quarter. Catalytic Wealth RIA LLC now owns 9,086 shares of the biopharmaceutical company's stock valued at $493,000 after acquiring an additional 2,258 shares during the last quarter. Covestor Ltd boosted its stake in Bristol-Myers Squibb by 22.4% during the 1st quarter. Covestor Ltd now owns 5,558 shares of the biopharmaceutical company's stock worth $302,000 after acquiring an additional 1,019 shares during the last quarter. Finally, Bahl & Gaynor Inc. grew its holdings in Bristol-Myers Squibb by 2.7% during the first quarter. Bahl & Gaynor Inc. now owns 44,568 shares of the biopharmaceutical company's stock valued at $2,417,000 after purchasing an additional 1,183 shares during the period. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Samit Hirawat acquired 1,830 shares of the company's stock in a transaction on Friday, November 1st. The stock was bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Price Performance

Shares of BMY stock traded down $2.28 on Friday, reaching $56.22. The stock had a trading volume of 21,259,228 shares, compared to its average volume of 10,839,494. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The firm's 50-day moving average is $52.73 and its two-hundred day moving average is $47.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business's revenue was up 8.4% on a year-over-year basis. During the same period last year, the firm posted $2.00 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.27%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's payout ratio is presently -66.85%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on BMY shares. BMO Capital Markets increased their target price on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating for the company in a report on Tuesday, July 23rd. StockNews.com upgraded Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 29th. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday. Finally, Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They set a "market perform" rating and a $56.00 target price for the company. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.